Paris – Cellectis (Alternext: ALCLS), the genome engineering specialist,

has announced the completion of a structurally important transaction concerning its

subsidiary Cellectis bioresearch, which specializes in designing, developing and marketing

products and services essentially for academic and biopharmaceutical industry

researchers: a simplified legal structure, with Ectycell merged into Cellectis bioresearch;

and a reinforced equity position, with a €3.5 million contribution subscribed for by Caisse

des Dépôts.

Ectycell’s tie-up with Cellectis bioresearch will enable Cellectis bioresearch to enrich and

sustain its offering, synergistically combining the technologies of targeted gene editing and

iPS cell-derived models.

The new structure has the advantage of being more uniform with the aim of providing

disruptive innovations that run the gamut from in vitro genetic diversity control for R&D to

client-specific turnkey solutions.

As part of this rationalization process, the Cellectis Group plans to bring together the

activities of Cellectis bioresearch and Ectycell at a single production facility.

On December 30, 2013, all of Ectycell’s shares were contributed to Cellectis bioresearch,

which also carried out a capital increase of €3.5 million euros in cash, fully subscribed for

by Caisse des Dépôts, in accordance with the commitments made under the partnership

initiated in January 2012.

Following these transactions, Cellectis now holds 75.5% of the share capital of Cellectis

bioresearch, while Caisse des Dépôts holds 24.5%.

A stronger equity position was essential to reinforcing Cellectis bioresearch’s autonomy

and its capacity for innovation in a competitive environment where major players based in

the United States and Japan tend to hold sway.

This investment reflects the priority placed by the Caisse des Dépôts group, as a

privileged partner of French state and local authorities, on helping SMEs raise capital and

foster innovation. Caisse des Dépôts initiated this investment under the convention signed

with the French state in 2008 to support Innovation Platforms in line with public policy on

competitiveness clusters.

About Cellectis

Founded in Paris in 1999, the Cellectis Group bases its work on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Cellectis was co-founded by André Choulika, its Chairman and CEO, and David Sourdive, Executive Vice President of Corporate Development, and is now one of the world’s top companies in the field of genome engineering, with revenue of €21 million in 2012. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, toxicity testing, and regenerative medicine.

The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. The Group’s clients and partners include University College London (UCL), the National Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer, and Limagrain. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (ALCLS.PA) in Paris.

For more information, visit our website: www.cellectis.com.

About the Caisse des Dépôts group

Caisse des Dépôts, together with its subsidiaries, is a French state financial institution serving as a long-term investor in support of the public interest and local economic development. Its mandate was reaffirmed by the Economic Modernization Act (LME) of August 4, 2008.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country.

Contact:

Press contacts

Cellectis

Philippe Valach, +33 (0)1 81 69 16 00

media@cellectis.com

or

Caisse des Dépôts group

Claude Schneegans, +33 (0)1 49 55 68 58

claude.schneegans@caissedesdepots.fr